Patents by Inventor Yifeng Frank Jing

Yifeng Frank Jing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12364714
    Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: July 22, 2025
    Assignee: ADICET THERAPEUTICS, INC.
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li
  • Patent number: 12221480
    Abstract: The present application is directed to agents that bind an epitope specific to a ?3 ?? TCR. Such agents can be, but are not limited to, an antibody or fragment thereof. Also described herein are methods for using the agents, e.g., to expand or selectively expand ?3 ?? T cells. Also described herein are methods of using expanded ?3 ?? T cells for treatment of a subject in need thereof.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: February 11, 2025
    Inventors: Aya Jakobovits, Daulet Kadyl Satpayev, Orit Foord, Yifeng Frank Jing, Hui Shao, Jason Michael Romero, Mary Michael Brody, Matthew Ian Hoopes
  • Publication number: 20230257462
    Abstract: The present application is directed to agents that bind an epitope specific to a ?3 ?? TCR. Such agents can be, but are not limited to, an antibody or fragment thereof. Also described herein are methods for using the agents, e.g., to expand or selectively expand ?3 ?? T cells. Also described herein are methods of using expanded ?3 ?? T cells for treatment of a subject in need thereof.
    Type: Application
    Filed: November 15, 2018
    Publication date: August 17, 2023
    Inventors: Aya Jakobovits, Daulet Kadyl Satpayev, Orit Foord, Yifeng Frank Jing, Hui Shao, Jason Michael Romero, Mary Michael Brodey, Matthew Ian Hoopes
  • Publication number: 20230009275
    Abstract: The present invention relates to methods employing soluble multivalent activating agents for the selective in vitro and ex vivo activation and expansion ?? T-cell population(s), including specific ?? T-cell subpopulation(s) of interest and admixtures thereof, and methods for using the same for therapeutic purposes. Methods and compositions of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Application
    Filed: December 3, 2020
    Publication date: January 12, 2023
    Inventors: Aya JAKOBOVITS, Daulet SATPAYEV, Orit FOORD, Yifeng Frank JING, Hui SHAO, Arun BHAT
  • Publication number: 20220372439
    Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Application
    Filed: April 11, 2022
    Publication date: November 24, 2022
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li
  • Publication number: 20220218747
    Abstract: The present invention relates to methods for the selective in vivo activation, expansion and/or maintenance of ?? T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Methods and compositions of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Application
    Filed: December 3, 2019
    Publication date: July 14, 2022
    Inventors: Aya JAKOBOVITS, Daulet SATPAYEV, Orit FOORD, Yifeng Frank JING, Hui SHAO
  • Patent number: 11299708
    Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: April 12, 2022
    Assignee: ADICET BIO, INC.
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li
  • Publication number: 20210388100
    Abstract: Aspects of the invention include compositions and methods for treatment of hematological tumors with engineered or non-engineered ??-T cells. In some embodiments, the ??-T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-CD20 binding domain or anti-B cell maturation antigen (BCMA) binding domain, a CD8 hinge and transmembrane domain, a costimulatory domain, a CD3 ? signalling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as a sIL 15 domain.
    Type: Application
    Filed: October 1, 2019
    Publication date: December 16, 2021
    Inventors: Daulet Kadyl Satpayev, Marissa Ann Herrman, Jason Michael Romero, Yifeng Frank Jing, Zili An, Aya Jakobovits
  • Publication number: 20210388109
    Abstract: Aspects of the invention include compositions and methods for treatment of solid tumors with engineered or non-engineered ??-T cells. In some embodiments, the ??-T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-TryD binding domain, a CD8? hinge and transmembrane domain, a costimulatory domain, a 003? signalling domain, a combination thereof, or all thereof. The CAR construct can contain an anti-GPC3 binding domain, a CD8? hinge and transmembrane domain, a costimulatmy domain, a CD3? signalling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as a sIL 15 domain.
    Type: Application
    Filed: October 1, 2019
    Publication date: December 16, 2021
    Inventors: Daulet Kadyl Satpayev, Marissa Ann Herrman, Jason Michael Romero, Yifeng Frank Jing, Zili An, Aya Jakobovits
  • Publication number: 20190119634
    Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and ad-mixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Application
    Filed: May 12, 2017
    Publication date: April 25, 2019
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li